Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect

Thrombosis Research

Volumn 132, Issue 2, 2013, Pages 256-262

  Mathijssen, Natascha C J ^a   Masereeuw, Rosalinde ^b   Holme, Pal Andre ^c   Van Kraaij, Marian G J ^d   Laros Van Gorkom, Britta A P ^a   Peyvandi, Flora ^e   Van Heerde, Waander L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Sanquin Blood Bank South East ^*  (Netherlands)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Coagulation; Factor VII; Hemostasis; Pharmacokinetics; Plasma derived factor VII; Recombinant activated factor VII

Indexed keywords

PLASMA DERIVED FACTOR 7; RECOMBINANT ACTIVATED FACTOR 7; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CLINICAL ARTICLE; DRUG HALF LIFE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME;

AREA UNDER THE CURVE; AUC; CL; CMAX; COAGULATION; FACTOR VII; FVII; HALF-LIFE; HB; HEMOGLOBIN; HEMOSTASIS; INCREMENTAL IN VIVO RECOVERY; IVR; MEAN RESIDENCE TIME; MRT; NCA; NON-COMPARTMENTAL ANALYSIS; OCA; ONE-COMPARTMENTAL ANALYSIS; PDFVII; PEAK PLASMA CONCENTRATION OF A DRUG AFTER ADMINISTRATION; PHARMACOKINETICS; PLASMA-DERIVED FACTOR VII; RECOMBINANT ACTIVATED FACTOR VII; RFVIIA; T1/2; TOTAL BODY CLEARANCE; VOLUME OF DISTRIBUTION AT STEADY-STATE; VSS;

ADULT; BLOOD COAGULATION TESTS; CROSS-OVER STUDIES; FACTOR VII DEFICIENCY; FACTOR VIIA; FEMALE; HALF-LIFE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84883819957     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.05.027     Document Type: Article

References (21)

1. B.A. Konkle, L.S. Ebbesen, E. Erhardtsen, R.P. Bianco, T. Lissitchkov, and L. Rusen Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors J Thromb Haemost 5 2007 1904 1913
2. G. Mariani, B.A. Konkle, and J. Ingerslev Congenital factor VII deficiency: therapy with recombinant activated factor VII - a critical appraisal Haemophilia 12 2006 19 27
3. N.C. Mathijssen, R. Masereeuw, K. Verbeek, J.M. Lavergne, J.M. Costa, and W.L. van Heerde Prophylactic effect of recombinant factor VIIa in factor VII deficient patients Br J Haematol 125 2004 494 499
4. W.Y. Tcheng, J. Donkin, S. Konzal, and W.Y. Wong Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency Haemophilia 10 2004 295 298
5. C.M. Lindley, W.T. Sawyer, B.G. Macik, J. Lusher, J.F. Harrison, and K. Baird-Cox Pharmacokinetics and pharmacodynamics of recombinant factor VIIa Clin Pharmacol Ther 55 1994 638 648
6. G.E. Rivard, I. Kovac, M. Kunschak, and P. Thone Clinical study of recovery and half-life of vapor-heated factor VII concentrate Transfusion 34 1994 975 979
7. G. Mariani, P.M. Mannucci, M.G. Mazzucconi, and A. Capitanio Treatment of congenital factor VII deficiency Thromb Haemost 39 1978 675 682
8. G.W.R. Dike, D. Griffiths, E. Bidwell, T.J. Snape, and C.R. Riza A factor VII concentrate for therapeutic use Br J Haematol 45 1980 107 118
9. B. Charpiat, S. Laporte, P. Mismetti, G. Debize, and C. Ducerf Perioperative pharmacokinetics of factor VII concentrate during liver surgery in a patient with congenital factor VII deficiency: an individual mathematical model Blood Coagul Fibrinolysis 13 2002 457 460
10. M. Berrettini, G. Mariani, M. Schiavoni, A. Rocino, T. Di Paolantonio, and G. Longo Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency Haematologica 86 2001 640 645
11. M. Levi, M. Peters, and H.R. Buller Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review Crit Care Med 33 2005 883 890
12. M.J. Fridberg, U. Hedner, H.R. Roberts, and E. Erhardtsen A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects Blood Coagul Fibrinolysis 16 2005 259 266
13. T. Klitgaard, and T.G. Nielsen Overview of the human pharmacokinetics of recombinant activated factor VII Br J Clin Pharmacol 65 2008 3 11
14. J.D. Powers Statistical considerations in pharmacokinetic study design Clin Pharmacokinet 24 1993 380 387
15. J.H. Morrissey, B.G. Macik, P.F. Neuenschwander, and P.C. Comp Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation Blood 81 1993 734 744
16. R. Biggs, and E. Bidwell A method for the study of antihaemophilic globulin inhibitors with reference to six cases Br J Haematol 5 1959 379 395
17. R. Gopalakrishnan, U. Hedner, S. Ghosh, R.C. Nayak, T.C. Allen, and U.R. Pendurthi Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa) J Thromb Haemost 8 2010 301 310
18. J.H. Lawson, S. Butenas, N. Ribarik, and K.G. Mann Complex-dependent inhibition of factor VIIa by antithrombin III and heparin J Biol Chem 268 1993 767 770
19. I.M. Nilsson, and U. Hedner Characteristics of various factor VIII concentrates used in treatment of haemophilia A Br J Haematol 37 1977 543 557
20. L.C. Petersen, T. Elm, M. Ezban, T.N. Krogh, D.M. Karpf, and A. Steino Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors Thromb Haemost 101 2009 818 826
21. L.V. Rao, O. Nordfang, A.D. Hoang, and U.R. Pendurthi Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity Blood 85 1995 121 129